Trial Profile
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis
- 07 Nov 2016 New trial record